Dr. Wittaya Wanpen, Deputy Managing Director, Business Development and Strategy Office at Praram 9 Hospital Public Company Limited (SET: PR9), expressed optimism about the hospital’s performance in the third quarter of 2025, driven by increased service utilization from both Thai and international patients, with a notable rise in the latter group.
In July 2025, PR9 reported higher revenue from medical services compared to June 2025 and July 2024, reflecting its capability to effectively serve patients across its 32 medical centers. The strategic emphasis on five key medical centers—nephrology, cardiology, neurology, orthopedic surgery, and minimally invasive surgery—has resulted in high bed occupancy rates for inpatients.
To enhance its service offerings, PR9 has bolstered its team with specialized medical experts and invested in advanced medical innovations and equipment to manage complex diseases without disruptions. This has led to an increase in non-surgical heart valve replacements, over 1,400 kidney transplants, and treatments for cerebrovascular obstructions, Parkinson’s disease, and dementia, among others.
The hospital has also expanded its Telemedicine services to 24/7 availability and introduced the 9 SMART platform on the LINE application, allowing patients to manage their healthcare seamlessly anytime, anywhere. Additionally, amidst economic downturns, PR9 has launched promotions and financial tools to assist both cash-paying and insured patients with copayment needs.
Dr. Wittaya further stated that the hospital aims to achieve double-digit growth in medical service revenue, building on the 4.74 billion baht reported in 2024. This target aligns with the influx of international patients exceeding expectations, particularly from the Arab world and the CLMV (Cambodia, Laos, Myanmar, Vietnam) region.
Prior to the COVID-19 pandemic, PR9 invested in Building B to accommodate patient growth and opened its International Center, staffed with experienced physicians for international patient care. This ensured high-quality care and successful treatment outcomes, leading to positive word-of-mouth recommendations. Consequently, the number of foreign patients has continued to grow.
Dr. Wittaya noted that by the second quarter of 2025, the average proportion of international patients rose to 26-27%, compared to 15-16% at the close of 2024. He further projected that by the end of the year, this figure is expected to stabilize at 26-28%.
As of 11:00 AM (Bangkok time) on Monday, the share price of PR9 rose by 1.30% or THB 0.30 to THB 23.40, with a trading value of THB 19.64 million.
